{
  "abstract": "Background: Although effective, current chimeric antigen receptor T-cell (CAR-T) production methods—centralized, manual, and complex—are cost-intensive, time-consuming, and prone to variability. AIDPATH (AI-Powered Decentralized Production for Advanced Therapies in the Hospital) proposes a decentralized, automated alternative that integrates patient-specific data; optimizes resource use; and potentially improves cell viability, manufacturing efficiency, and patient outcomes.\n\nObjective: The aim of this study was to compare CAR-T therapy produced by the AIDPATH platform to both ciltacabtagene autoleucel (cilta-cel) and standard of care (SoC) for patients with triple-class refractory multiple myeloma (MM) over a 40-year time horizon from the hospital perspective in Germany.\n\nMethods: A partitioned survival model reflecting 3 health states (progression-free disease, progressed disease, and death) was used. The analysis used clinical trial data for cilta-cel, real-world data for SoC, and estimated parameters for AIDPATH due to the developmental status of the platform. The primary outcome was the incremental cost-effectiveness ratio; secondary outcomes included sensitivity and scenario analyses.\n\nResults: On the basis of the model used in this analysis, AIDPATH was dominant compared to both cilta-cel and SoC. Most costs for CAR-T therapies were driven by acquisition and adverse events. Sensitivity analyses showed that the results were most influenced by discount rates and assumptions about progression-free survival. Scenario analyses, including reduced adverse events and shorter vein-to-vein times for AIDPATH, further supported its cost-effectiveness.\n\nConclusions: This is the first study to assess the cost-effectiveness of a CAR-T product generated with AI support in Germany from the hospital perspective. AIDPATH was found to be a cost-effective alternative to both cilta-cel and SoC, making it a promising option for future implementation. Although further data are needed, this study provides valuable guidance for health care stakeholders, reimbursement discussions, and future research.",
  "abstract_shown": true,
  "affiliations": [
    "Panaxea 's-Hertogenbosch The Netherlands",
    "Department Bio-adaptive Production Fraunhofer Institute for Production Technology IPT Aachen, North Rhine-Westphalia Germany",
    "Faculty of Health, Medicine and Life Sciences Maastricht University Maatricht, Limburg The Netherlands"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Iris W A Boot",
      "orcid": "0000-0003-4760-412X"
    },
    {
      "affs": [
        1
      ],
      "name": "Anna Louisa Weltin",
      "orcid": "0009-0008-5522-9327"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Ysanne de Graaf",
      "orcid": "0000-0003-0024-7276"
    },
    {
      "affs": [
        0
      ],
      "name": "Hubertus J M Vrijhoef",
      "orcid": "0000-0002-5539-4671"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0bff3tbs0z4n1.bib",
  "cited_by": 0,
  "doi": "10.2196/92253",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13718277/",
  "id": "0bff3tbs0z4n1",
  "issns": [
    "2369-1999"
  ],
  "landing_url": "https://doi.org/10.2196/92253",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Paper"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7127268899",
  "pdf_url": null,
  "pmcid": "PMC13718277",
  "pmid": "42868529",
  "published": "2026-10-13",
  "publisher": "JMIR Publications Inc.",
  "ris": "https://research.draconitic.com/paper/0bff3tbs0z4n1.ris",
  "sources": [
    {
      "first_seen": "2026-11-02T12:22:20Z",
      "native_id": "PMC13718277",
      "source": "pmc",
      "url": "https://doi.org/10.2196/92253"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study",
  "title_text": "Cost-Effectiveness of AI-Powered Decentralized Production for Advanced Therapies in the Hospital–Generated Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma From a German Hospital Perspective: Early Health Technology Assessment Study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-02T12:22:20Z",
  "url": "https://research.draconitic.com/paper/0bff3tbs0z4n1",
  "venue": "JMIR Cancer",
  "versions": []
}